What is the recommended treatment approach for depression in an elderly patient, including first‑line medication choice, dosing, monitoring, and adjunct therapies?

Treatment of Depression in Elderly Patients

First-Line Medication Recommendations

Start with sertraline 25–50 mg daily or citalopram 10 mg daily as your first-line agent, avoiding paroxetine and fluoxetine entirely. 1

The American Academy of Family Physicians explicitly designates citalopram, sertraline, venlafaxine, and bupropion as preferred first-line agents for older adults, while stating that paroxetine and fluoxetine should NOT be used in this population. 1 Among these options, citalopram and sertraline receive the highest ratings for both efficacy and tolerability in older adults. 1

Specific Dosing Strategy

• Sertraline: Start at 25–50 mg once daily (half the standard adult dose), titrate to target 50–100 mg daily. 1, 2 No age-based dose adjustment is required beyond the initial 50% reduction. 3
• Citalopram: Start at 10 mg once daily, with a strict maximum of 20 mg/day in patients >60 years due to dose-dependent QT prolongation. 1, 4
• Escitalopram: Start at 5–10 mg once daily, with a maximum of 10 mg/day in elderly patients. 1, 4

The rationale for starting at approximately 50% of standard adult doses is slower metabolism and increased sensitivity to adverse effects in older adults. 1

---

Alternative First-Line Options Based on Symptom Profile

When Cognitive Symptoms Dominate

Bupropion is the most effective choice when difficulty concentrating, indecisiveness, or mental fog are prominent, offering dopaminergic/noradrenergic effects with lower rates of cognitive side effects and sexual dysfunction. 1, 5 Start at 50% of the usual adult dose and adjust for renal/hepatic impairment. 1

Venlafaxine (SNRI) is equally preferred as first-line therapy when cognitive symptoms are prominent, particularly because it has dopaminergic/noradrenergic effects with lower rates of cognitive side effects. 1

When Insomnia or Poor Appetite Are Prominent

Mirtazapine is appropriate when insomnia or poor appetite dominate the clinical picture, though monitor closely for sedation and weight gain. 1 In elderly patients, start at the low end of the dosing range due to decreased clearance and greater risk of confusion and over-sedation. 6

---

Medications to Avoid in Elderly Patients

Absolutely Contraindicated

• Paroxetine: Highest anticholinergic effects among SSRIs, highest sexual dysfunction rates, and potent CYP2D6 inhibition. 1
• Fluoxetine: Greater risk of agitation, very long half-life, and significant drug-interaction potential. 1
• Tertiary-amine TCAs (amitriptyline, imipramine): Potentially inappropriate per Beers Criteria due to severe anticholinergic effects, cardiac toxicity, and increased cardiac arrest risk (OR 1.69). 1

---

Critical Safety Considerations

Suicide Risk: Age-Dependent Effect

Antidepressants are protective against suicidal behavior in adults over 65 years (OR 0.06,95% CI 0.01–0.58), contrasting sharply with increased risk in younger adults. 1 Despite this protective effect, close monitoring during the initial 1–2 months remains essential. 1

Upper GI Bleeding Risk

Upper GI bleeding risk increases substantially with age when using SSRIs: 4.1 hospitalizations per 1,000 adults aged 65–70 years and 12.3 hospitalizations per 1,000 octogenarians. 1 Risk multiplies dramatically (adjusted OR 15.6) when SSRIs are combined with NSAIDs. 1 Add a proton pump inhibitor or misoprostol for gastroprotection if NSAIDs cannot be discontinued. 1

Hyponatremia

SSRIs cause clinically significant hyponatremia in 0.5–12% of elderly patients, typically occurring within the first month of treatment. 1 Elderly patients are at substantially greater risk due to age-related changes in renal function and ADH regulation. 1 Check sodium levels within the first month of SSRI initiation. 1

Cardiac Safety

Citalopram and escitalopram cause dose-dependent QT prolongation; never exceed 20 mg/day citalopram or 10 mg/day escitalopram in patients >60 years. 1 Monitor ECG if using higher doses of escitalopram or if cardiac risk factors are present. 1

Venlafaxine requires blood pressure monitoring as it can worsen hypertension. 1

---

Monitoring Requirements

Initial Phase (Weeks 1–8)

• Week 4 and Week 8: Formal efficacy assessment using standardized scales (e.g., PHQ-9, Geriatric Depression Scale). 1
• First 30 days: Monitor for hyponatremia (check sodium), bleeding risk (especially if on NSAIDs/anticoagulants), and falls risk. 1
• Throughout treatment: Assess for bleeding, particularly if patient takes antiplatelet agents or anticoagulants. 1

Ongoing Monitoring

• Track both mood and cognitive symptoms using standardized measures. 1
• Monitor for extrapyramidal symptoms if using venlafaxine at higher doses. 1
• Do not discontinue monitoring after initial titration, as hyponatremia and bleeding can occur at any time. 1

---

Treatment Duration

Continue treatment for 4–12 months after achieving remission for a first episode of major depressive disorder. 1, 5 For patients with ≥3 prior episodes, consider indefinite maintenance at the lowest effective dose because recurrence risk reaches ~90% after the third episode. 1

Continued treatment after remission protects against recurrence. 1

---

Adjunct Therapies

Psychotherapy

Psychotherapy is equally effective as pharmacotherapy, with treated older adults more than twice as likely to achieve remission compared to no treatment (OR 2.47–2.63). 1 Cognitive-behavioral therapy, interpersonal therapy, and psychodynamic therapy are all evidence-based options. 5

Exercise Programs

Aerobic exercise programs have a moderate antidepressant effect (standardized mean difference -0.82) and can be used as adjunctive treatment. 1

Social Interventions

Addressing social isolation and loneliness through referral to local social assistance programs is crucial. 1 Optimizing nutrition and encouraging social engagement are essential components of comprehensive care. 1

---

Common Pitfalls to Avoid

• Do not use standard adult starting doses—always reduce by approximately 50%. 1
• Do not prescribe paroxetine or fluoxetine as first-line agents in older adults. 1
• Do not combine SSRIs with NSAIDs without gastroprotection given the 15-fold increased bleeding risk. 1
• Do not exceed 20 mg/day citalopram or 10 mg/day escitalopram in patients >60 years due to QT prolongation risk. 1
• Do not use tertiary-amine TCAs (amitriptyline, imipramine) due to severe anticholinergic burden and cardiac risks. 1
• Do not prescribe antidepressants for mild depression or subsyndromal symptoms without a current moderate-to-severe episode. 5

---

Augmentation Strategy for Partial Response

If a patient achieves only partial response to a first-line SSRI after 6–8 weeks at adequate dosing, add bupropion SR 150 mg daily rather than switching antidepressants. 1 The STAR*D trial demonstrated that switching and augmenting have comparable efficacy, but augmentation results in fewer discontinuation symptoms (e.g., dizziness, anxiety). 1

---

Special Populations

Patients with Dementia and Frailty

Provide treatments considering risk of adverse effects, comorbidities, and behavioral/psychological symptoms. 1 Among SSRIs, fluoxetine is generally not recommended due to its long half-life and side effects. 1 Venlafaxine, vortioxetine, and mirtazapine are safer options in terms of drug interactions for patients with dementia and frailty. 1

Patients with Cardiovascular Disease

Sertraline is a safe option for patients with coronary heart disease and heart failure, with lower risk of QTc prolongation compared to other SSRIs. 1 Tricyclic antidepressants are contraindicated in elderly patients with heart failure due to hypotension, worsening heart failure, and arrhythmias. 1